Free Trial
NASDAQ:OTLK

Outlook Therapeutics Q2 2025 Earnings Report

Outlook Therapeutics logo
$1.90 +0.03 (+1.60%)
Closing price 06/6/2025 04:00 PM Eastern
Extended Trading
$1.89 -0.01 (-0.53%)
As of 06/6/2025 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Outlook Therapeutics EPS Results

Actual EPS
-$0.40
Consensus EPS
-$0.55
Beat/Miss
Beat by +$0.15
One Year Ago EPS
N/A

Outlook Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.70 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Outlook Therapeutics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 15, 2025
Conference Call Time
12:30PM ET

Upcoming Earnings

Outlook Therapeutics' Q3 2025 earnings is scheduled for Wednesday, August 13, 2025, with a conference call scheduled on Thursday, August 14, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Outlook Therapeutics Earnings Headlines

"I'm risking my reputation on this"
Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.
Analysts Issue Forecasts for OTLK FY2026 Earnings
Q3 EPS Forecast for Outlook Therapeutics Boosted by Analyst
See More Outlook Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Outlook Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Outlook Therapeutics and other key companies, straight to your email.

About Outlook Therapeutics

Outlook Therapeutics (NASDAQ:OTLK), operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

View Outlook Therapeutics Profile

More Earnings Resources from MarketBeat